company background image
TLPH logo

Talphera NasdaqGM:TLPH Stock Report

Last Price

US$1.03

Market Cap

US$18.7m

7D

-8.0%

1Y

47.1%

Updated

28 Mar, 2024

Data

Company Financials +

TLPH Stock Overview

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.

TLPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Talphera, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Talphera
Historical stock prices
Current Share PriceUS$1.03
52 Week HighUS$1.61
52 Week LowUS$0.42
Beta0.54
1 Month Change-24.82%
3 Month Change40.14%
1 Year Change47.14%
3 Year Change-96.97%
5 Year Change-98.49%
Change since IPO-98.87%

Recent News & Updates

Recent updates

AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well

Aug 18

AcelRx Pharmaceuticals: Finally, Plan B

Jun 06

AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers

Mar 16

AcelRx Pharmaceuticals: The Fog Is Getting Thicker

Jan 14

AcelRx: Battered And Bruised But Ready For Recovery In 2022

Jan 05

AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?

Oct 02

AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm

Jul 27

FDA agrees with AcelRx to update promotional materials for Dsuvia

Jun 17

Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now

Jun 11
Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now

AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles

May 31

When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Turn A Profit?

Feb 03
When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Turn A Profit?

Shareholder Returns

TLPHUS PharmaceuticalsUS Market
7D-8.0%2.2%0.2%
1Y47.1%25.5%28.1%

Return vs Industry: TLPH exceeded the US Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: TLPH exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is TLPH's price volatile compared to industry and market?
TLPH volatility
TLPH Average Weekly Movement18.0%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: TLPH's share price has been volatile over the past 3 months.

Volatility Over Time: TLPH's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200515Vince Angottihttps://talphera.com

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.

Talphera, Inc. Fundamentals Summary

How do Talphera's earnings and revenue compare to its market cap?
TLPH fundamental statistics
Market capUS$18.67m
Earnings (TTM)-US$10.29m
Revenue (TTM)US$651.00k

26.8x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TLPH income statement (TTM)
RevenueUS$651.00k
Cost of RevenueUS$498.00k
Gross ProfitUS$153.00k
Other ExpensesUS$10.44m
Earnings-US$10.29m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.61
Gross Margin23.50%
Net Profit Margin-1,580.18%
Debt/Equity Ratio0%

How did TLPH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.